Commentary: MassHealth GLP-1 Coverage Cuts Shift Costs, Not Savings

In a commentary piece, a CPA and nurse argues that Massachusetts insurers' decisions to end GLP-1 coverage for obesity, including MassHealth's move affecting about 22,000 members and the Group Insurance Commission's similar cut for public employees, produce illusory savings. The author cites trial data showing patients regain weight and cardiometabolic gains reverse within a year of stopping treatment, and notes insurers like Point32Health project over $100 million in savings even as premiums rise 10.4 percent for 2027. The piece argues this amounts to cost-shifting onto future payers and patients rather than genuine cost reduction, disproportionately harming lower-income residents. The author calls for Massachusetts to negotiate drug prices, adopt evidence-based eligibility criteria, and require insurers to publicly report health and cost outcomes from coverage restrictions.

Pharmacy · Managed Care · Finance